Fascinating approach to biotech policy simulation. The observation about status quo bias limiting extreme options is super relevant to real policymaking too, not just game outcomes. The emerging market healthcare gap problem is somethin I've seen firsthand in deployment projects, institutional capacity matters way more than capital availability. The multi-indicator tradeoff design sounds like a smart way to force players into realistic constraint thinking.
Institutional capacity is a massive problem in healthcare. We didn't get down to that level (we stayed at the nation-state layer), but even within countries, there are huge gaps in what hospitals can do with their know-how and organizational structures.
Fascinating approach to biotech policy simulation. The observation about status quo bias limiting extreme options is super relevant to real policymaking too, not just game outcomes. The emerging market healthcare gap problem is somethin I've seen firsthand in deployment projects, institutional capacity matters way more than capital availability. The multi-indicator tradeoff design sounds like a smart way to force players into realistic constraint thinking.
Institutional capacity is a massive problem in healthcare. We didn't get down to that level (we stayed at the nation-state layer), but even within countries, there are huge gaps in what hospitals can do with their know-how and organizational structures.